Extended Treatment Access Study of MT-3724 for Subjects with Relapsed non-Hodgkin’s B-Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia Who Have Completed Phase I/Ib Study MT-3724_NHL_001_US
You are being asked to take part in this study because you have completed the MD Anderson clinical research study, 2014-0504, without any intolerable side effects. The non-Hodgkin’s B-cell lymphoma (NHL) or chronic lymphocytic leukemia (CLL) did not get worse while you were taking MT-3724.' The goal of this clinical research study is to provide continued access to MT-3724 to patients who were taking it as part of the 2014-0504 study. Researchers also want to learn about the safety of continuing to receive MT-3724.
Treatment Location: N/A
IRB Review and Approval Date: 01/20/2016
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: